Taking stock of the drug industry, from the lab to the medicine chestJune 22, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Medicare puts out new details for covering the Alzheimer's drug Leqembi, as the health system readies for potential approval The floodgates could open if the FDA approves Leqembi next month. Medicare just put out new details about how it'd cover the drug. By Rachel Cohrs STAT+ | FDA grants conditional approval to Sarepta's gene therapy for Duchenne muscular dystrophy Regulators restricted the treatment to younger patients, with additional data required to broaden its use. By Jason Mast and Adam Feuerstein STAT+ | The strategy behind the pharmaceutical industry's flurry of lawsuits challenging drug pricing reform Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. By Rachel Cohrs Dr. Edwin P. Ewing, Jr./CDC Opinion: The FDA's approval of a new gene therapy for Duchenne muscular dystrophy won't help me — but it gives me hope If Sarepta's gene therapy SRP-9001 succeeded through this accelerated approval pathway, then many more can as well. By Hawken Miller Listen: Messy PBM conflicts, debatable vaccines, & the future of flu season STAT's Bob Herman joins us to explain his investigation into some brazen conflicts of interest in the world of prescription drug pricing. By Damian Garde and Meg Tirrell More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments